	·	_	
Please type	a plus sign (+) inside this box>	+	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	(Use as many s	heets as necessary)	_
Sheet	. 1	of	

	Complete if Known	· -
Application Number	Unassigned	
Filing Date	July 25, 2003	
First Named Inventor	Kasid et al.	
Group Art Unit	Unassigned	
Examiner Name	Unassigned	
Attomey Docket Number	223316	

				U.S. PATENT DOCUMENTS		
		U.S. Patent Do	cument			
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
	AA	5,801,154		Baracchini et al.	Sept. 1, 1998	

			OTHER - NON PATENT LITERATURE DOCUMENTS		
Γ	Examiner	Doc.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	Trans	lation
	Initials	No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*+
1	SH	AB	AGRAWAL, "Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides," <i>Biochimica et Biophysica Acta 1489</i> , 53-68 (1999)		
ſ		AC	ASHKENAZI et al., "Death Receptors: Signaling and Modulation," Science, 281 (5381), 1305-1308 (1998)		
		AD	BERTIN et al., "Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis," <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 94 (4), 1172-1176 (1997)		
ſ		AE	BLUNDELL et al., "Knowledge-based prediction of protein structures and the design of novel molecules," <i>Nature</i> , 326 (6111), 347-352 (1987)		
	T	AF	BOLDIN et al., "Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death," Cell, 85 (6), 803-815 (1996)		
		AF	CHINNAIYAN et al., "FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis," The Journal of Biological Chemistry, 271 (9), 4961-4965 (1996)		
		AG	CHIOU et al., "Inhibition of ICE-like Proteases Inhibits Apoptosis and Increases Virus Production during Adenovirus Infection," <i>Virology</i> , 244 (1), 108-118 (1998)	-	
		АН	CORPET, "Multiple sequence alignment with hierarchical clustering," Nucleic Acids Research, 16 (22), 10881-10890 (1988)		
		AI	CROOKE, "Molecular mechanisms of action of antisense drugs," Biochimica et Biophysica Acta 1489, 31-44 (1999)		
	(AJ	DARZYNKIEWICZ et al., "Features of Apoptotic Cells Measured by Flow Cytometry," Cytometry, 13 (8), 795-808 (1992)		
		AK	EARL et al., "Homology between DNA polymerases of poxviruses, herpesviruses, and adenoviruses: Nucleotide sequence of the vaccine virus DNA polymerase gene," Proceedings of the National Academy of Sciences of the United States of America, 83 (11), 3659-3663 (1986)		
		AL	GOKHALE et al., "Antisense raf Oligodeoxyribonucleotide Is a Radiosensitizer In Vivo," Antisense & Nucleic Acid Drug Development (The Antisense Journal), 9 (2), 191-201 (1999)		
		АМ	GOLTSEV et al., "CASH, a Novel Caspase Homologue with Death Effector Domains," The Journal of Biological Chemistry, 272 (32), 19641-19644 (1997)		
	,	AN	GRIFFITH et al., "Intracellular Regulation of TRAIL-Induced Apoptosis in Human Melanoma Cells," The Journal of Immunology, 161 (6), 2833-2840 (1998)		
	Í	ÃO	HAN et al., "Suppression of In Vivo Tumorigenicity of Human Lung Cancer Cells by Retrovirus-mediated Transfer of the Human Tumor Necrosis Factor-a cDNA," Respiratory Cell and Molecular Biology, 11 (3), 270-278 (1994)		
		AP	HEO et al., "Biology, Cytogenetics, and Sensitivity to Immunological Effector Cells of New Head and Neck Squamous Cell Carcinoma Lines," Cancer Research, 49 (18), 5167-5175 (1989)		
	di	AQ	HORREVOETS et al., "Vascular Endothelial Genes That Are Responsive to Tumor Necrosis Factor-σ In Vitro Are Expressed in Atherosclerotic Lesions, Including Inhibitor of Apoptosis Protein-1, Stannin, and Two Novel Genes," <i>Blood</i> , 93 (10), 3418-3431 (1999)		

._*:*`

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 2 of 23

	Complete if Known	
Application Number	Unassigned	
Filing Date	July 25, 2003	
First Named Inventor	Kasid et al.	
Group Art Unit	Unassigned	
Examiner Name	Unassigned	
Attorney Docket Number	223316	

		OTHER - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	T-0	lation
Examiner Initials	Doc. No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	lation No*
PA	AR	HU et al., "A Novel Family of Viral Death Effector Domain-containing Molecules That Inhibit Both CD-95- and Tumor Necrosis Factor Receptor-1-induced Apoptosis," The Journal of Biological Chemistry, 272 (15), 9621-9624 (1997)		
7 47	AS	HU et al., "I-FLICE, a Novel Inhibitor of Tumor Necrosis Factor Receptor-1- and CD-95-induced Apoptosis," <i>The Journal of Biological Chemistry</i> , 272 (28), 17255-17257 (1997)		_
1	AT	HU et al., "Adenovirus E1B 19K Protein Is Required for Efficient DNA Replication in U937 Cells," Virology, 227 (2), 295-304 (1997)		
7	AU	INBAL et al., "DAP kinase links the control of apoptosis to metastasis," <i>Nature</i> , 390 (6656), 180-184 (1997)		
17	AV	IRMLER et al., "Inhibition of death receptor signals by cellular FLIP," Nature, 388 (6638), 190-195 (1997)		
	AW ⁽	KASID et al., "Stress-responsive signal transduction: emerging concepts and biological significance," APOTOSIS GENES, Kluwer Academic Publishers, Boston, Chapter 4, pp. 85-117 (1998)		
	AX	KASID et al., "Ionizing radiation and TNF- α stimulate gene expression of a Thr/Tyr-protein phosphatase HVH1 and inhibitory factor IKB α in human squamous carcinoma çells," Molecular and Cellular Biochemistry, 173 (1 & 2), 193-197 (1997)		
	AY.	KASID et al., "Effect of Antisense c-raf-1 on Tumorigenicity and Radiation Sensitivity of a Human Squamous Carcinoma," Science, 243 (4896), 1354-1356 (1989)		
	AZ		-	
	BA /			
	BB 1	KUMAR et al., "Identification of a Novel Tumor Necrosis Factor-α-inducible Gene, SCC-S2, Containing the Consensus Sequence of a Death Effector Domain of Fas-associated Death Domain-like Interleukin-1β-converting Enzyme-inhibitory Protein," The Journal of Biological Chemistry, 275 (4), 2973-2978 (2000)		
	BC/	LENNON et al., "The I.M.A.G.E. Consortium: An Integrated Molecular Analysis of Genomes and Their Expression," GENOMICS, 33 (1), 151-152 (1996)		
	BD '	MILNER et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays," Nature Biotechnology, 15, 537-541 (1997)		
	B E	MORIMOTO et al., "Synergistic Effect of Tumor Necrosis Factor-σ- and Diphtheria Toxin-Mediated Cytotoxicity in Sensitive and Resistant Human Ovarian Tumor Cell Lines," The Journal of Immunology, 147 (8), 2609-2616 (1991)		
	BF	MUZIO et al., "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex," Cell, 85 (6) §17-827 (1996)		
	BG	NAKAI et al., "A Knowledge Base for Predicting Protein Localization Sites in Eukaryotic Cells," GENOMICS, 14, 897-911 (1992)		
	вн	NICOLETTI et al., "A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry," <i>Journal of Immunological Methods</i> , 139 (2), 271-279 (1991)		
	BIV	Cancer Cell Line," Biochemical and Biophysical Research Communications, 193 (3), 897-904 (1993)		
	ВЈ	PATEL et al., "Constitutive Modulation of Raf-1 Protein Kinase is Associated with Differential Gene Expression of Several Known and Unknown Genes," Molecular Medicine, Official Journal of the Molecular Medicine Society, 3 (10), 674-685 (1997)		

			<u> </u>		Complete if Known	
Substitute for fo	nm 1449A/B/PTO			Application Number	Unassigned	
INE	DRMATION	nisc	CLOSURE	Filing Date	July 25, 2003	
				First Named Inventor	Kasid et al.	
STATEMENT BY APPLICANT		PLICANI	Group Art Unit	Unassigned		
	(Use as many sheet	ts as ne	cessary)	Examiner Name	Unassigned	
Sheet	3	of	3	Attorney Docket Number	223316	

Evamias:	The control of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item to control of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item to control of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item to control of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item to control of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item to control of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item to control of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item to control of the author (in CAPITAL LETTERS).						
Initials	No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*+			
M	ВК	PATEL et al., "Identification of Seven Differentially Displayed Transcripts in Human Primary and Matched Metastatic Head and Neck Squamous Cell Carcinoma Cell Lines: Implications in Metastasis and/or Radiation Response," <i>Oral Oncology</i> , 33 (3), 197-203 (1997)					
	ВL	SACCHI et al., "Antiproliferative Effects of Cytokines on Squamous Cell Carcinoma," Archives of Otolaryngology-Head & Neck Surgery, 117 (3), 321-326 (1991)		i			
	ВМ	SATA et al., "Endothelial Cell Apoptosis Induced by Oxidized LDL Is Associated with the Down-regulation of the Cellular Caspase Inhibitor FLIP," The Journal of Biological Chemistry, 273 (50), 33103-33106 (1998)					
	BN	SRINIVASULA et al., "FLAME-1 a Novel FADD-like Anti-apoptotic Molecule That Regualtes Fas/TNFR1-induced Apoptosis," <i>The Journal of Biological Chemistry</i> , 272 (30), 18542-18545 (1997)					
	во	STEIN, "Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments," <i>Biochimica et Biophysica Acta 1489</i> , 45-52 (1999)					
	ВР	TEWARI et al., "CrmA, a Poxvirus-encoded Serpin, Inhibits Cytotoxic T-lymphocyte-mediated Apoptosis," The Journal of Biological Chemistry, 270 (39), 22705-22708 (1995)	-				
	BQ	THOME et al., "Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors," 386 (6624), 517-521 (1997)					
	BR	TROPPMAIR et al., "v-Raf/v-Myc Synergism in Abrogation of IL-13 Dependence: v-Raf Suppresses Apoptosis," <u>Mechanisms in B-Cell Neoplasia 1992</u> , Workshop at the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 453-460 (1992)					
	BS	WEISS et al., "Human Herpesvirus Type 8 and Kaposi's Sarcoma," Mongraphs Journal of the National Cancer Institute, (23), 51-54 (1998)					
A	ВТ	YEH et al., "Mitogen-activated Protein Kinase Kinase Antagonized Fas-associated Death Domain Protein-mediated Apoptosis by Induced FLICE-inhibitory Protein Expression," The Journal of Experimental Medicine, 188 (10), 1795-1802 (1998)					
				_			
				_			
	-						

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

	Please type a plus sign (+) inside this box	→
--	---	----------

FEB 0 9 2004

INFORMATION DISCLOSUE STATEMENT BY APPLICAN

(Use as many sheets as necessary) Sheet:of

	Complete if Known	
Application Number	10/627,571	
Filing Date	July 25, 2003	
First Named Inventor	Kasid et al.	
Group Art Unit	1623	
Examiner Name	Unassigned	
Attorney Docket Number	223316	

			U.	S. PATENT DOCUMENTS		
	U.S. Patent Document		cument			
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
 			-			
			1			

				FOREIGI	N PATENT DOCUMENTS			
		Fo	Foreign Patent Document		eign Patent Document		Trans	slation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No**
	;							

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item		
			Irans	lation
		(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*+
SPAH	_B U	GenBank, Accession No. AA116718, "The WashU-HHMI Mouse EST Project," ver. AA116718 GI:1671727 (1996)		
	BV	GenBank, Accession No. AA406630, "WashU-Merck EST Project 1997," ver. AA406630 GI:2064640 (1997):		
	BW	GenBank, Accession No. AA817594, "BDGP/HHMI Drosophila EST Project," ver. AA817594, GI:13767646 (2001)		
	ВХ	GenBank, Accession No. AF070671, "Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes," ver. AF070671.1 GI:3978237 (1999)		
	BY	GenBank, Accession No. AF098933, "Identification of a novel tumor necrosis factor- alpha-inducible gene, SCC-S2, containing the consensus sequence of a death effector domain of fas-associated death domain-like interleukin-1beta-converting enzyme- inhibitory protein," ver. AF098933.1 GI: 6851132 (2000).		
	ΒZ	GenBank, Accession No. AF098934, "Identification of a novel tumor necrosis factoralpha-inducible gene, SCC-S2, containing the consensus sequence of a death effector domain of fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein," ver. AF098934.1 GI:6851134 (2000)	-	
	CA	GenBank, Accession No. AF099936, "Identification of cellular factors involved in the differentiation of dendritic cells," ver. AF099936.1 GI:3860094 (1998)		
	СВ	GenBank, Accession No. U68132, "Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous carcinoma cell lines: Implications in metastasis and/or radiation response," ver. U68132 GI:2264403 (1998)		

Examiner Signature

Date Considered

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of

	Complete if Known	
Application Number	10/627,571	
Filing Date	July 25, 2003	
First Named Inventor	Kasid et al.	
Group Art Unit	1635	
Examiner Name	Ashen, Jon Benjamin	
Attorney Docket Number	223316	

				U.S. PATENT DOCUMENTS		
		U.S. Patent Doc	ument		ľ	
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
PHIL	CC	RE 30,985		Cartaya	June 29, 1982	
	CE	4,399,216		Axel et al.	Aug. 16, 1983	
	ÇF	4,551,433		DeBoer	Nov. 5, 1985	
	G	4,560,655		Baker	Dec. 24, 1985	•
	СН	4,657,866		Kumar	Apr. 14, 1987	_
	CI	4,767,704		Cleveland et al.	Aug. 30, 1988	
.] 7	Cl	4,745,051	l	Smith et al.	May 17, 1988	
7	CK	4,777,127		Suni et al.	Oct. 11, 1988	
	CL	4,816,567		Cabilly et al.	Mar. 28, 1989	
	CM	4,837,148		Cregg	June 6, 1989	
	CN	4,889,806		Olson et al.	Dec. 26, 1989	
1	CO	4,927,762		Darfler	May 22, 1990	
7	CP	4,929,555		Cregg et al.	May 29, 1990	
	CQ	4,959,314	<u> </u>	Mark et al.	Sep. 25, 1990	
	CR	5,013,830		Ohtsuka et al.	May 7, 1991	······································
	cs	5,091,309	Α	Schlesinger et al.	Feb. 25, 1992	
	СТ	5,149,655	Α	McCabe et al.	Sep. 22, 1992	
	CU	5,149,797	Α	Pederson et al.	Sep. 22, 1992	
	CV	5,185,440	Α	Davis et al.	Feb. 9, 1993	
	CW	5,206,152	Α	Sukhatme	Apr. 27, 1993	
 	СХ	5,217,879	Α	Huang et al.	Jun. 8, 1993	
	CY	5,219,740	A	Miller et al.	Jun. 15, 1993	
1	CZ	5,403,711	Α	Walder et al.	Apr. 4, 1995	
1	DA	5,422,120	Α	Kim	Jun. 6, 1995	·
	DB	5,491,133	A	Walder et al.	Feb. 13, 1996	
	DC	5,514,758	Α	Muller et al.	May 7, 1996	
	DD	5,530,101	A	Queen et al.	Jun. 25, 1996	
	DE	5,536,821	A	Agrawal et al.	July 16, 1996	
	DF	5,541,306	A	Agrawal et al.	July 30, 1996	
 	DG	5,550,111	A	Suhadolnik et al.	Aug. 27, 1996	
	DH	5,563,253	A	Agrawal et al.	Oct. 8, 1996	
	DI	5,565,552	A	Magda et al.	Oct. 15, 1996	
	DJ.	5,565,350	A	Kmiec	Oct. 15, 1996	
+	DK	5,567,810	A	Weis et al.	Oct. 22, 1996	
+-	DL	5,571,799	A	Tkachuk et al.	Nov. 5, 1996	
_	DM	5,574,142	A	Meyer, Jr. et al.	Nov. 12, 1996	
-	DN	5,580,859	A	Felgner et al.	Dec. 3, 1996	
+	DO	5,585,481	Â	Arnold, Jr. et al.	Dec. 17, 1996	
	DP	5,585,089	A	Queen et al.	Dec. 17, 1996	
	DQ	5,587,371	Â	Sessier et al.	Dec. 24, 1996	
	DR	5,587,361	A	Cook et al.	Dec. 24, 1996	
	DS	5,597,696	Â	Linn et al.	Jan. 28, 1997	
-+-	DT	5,610,018	A	Di Fiore et al.	Mar. 11, 1997	
-	DU	5,625,050	A	Beaton et al.		
-	DV	5,641,670	Ā	Treco et al.	Apr. 29, 1997 Jun. 24, 1997	

CH3 H	² DW	5,652,355	Α	Metelev et al.	July 29, 1997	
	DX	5,700,922	Α	Cook	Dec. 23, 1997	
	DY	5,776,745	A.	Ketner et al.	Jul. 7, 1998	
	DZ	5,801,154	Α	Baracchini et al.	Sept. 1, 1998	
	EA	5,919,773	Α	Monia et al.	Jul. 6, 1999	
	EB	5,939,598	Α	Kucherlapati et al.	Aug. 17, 1999	
	EC	5,958,773	Α	Monia et al.	Sep. 28, 1999	
	ED	6,333,314	B1	Kasid et al.	Dec. 25, 2001	
	EF	60/264,062		Kumar et al.		Jan. 26, 2001
	EG	60/281,780		Kasid et al.		Apr. 6, 2001
	EH	60/382,031		Gokhale et al.		May 22, 2002
	EI	60/371,126		Kasid et al.		Apr. 10, 2002
	EJ	60/281,779		Kasid et al.		Apr. 6, 2001
	EK	60/281,785		Kasid et al.		Apr. 6, 2001
	EL	60/371,116		Kasid et al.		Apr. 10, 2002
	EM	60/281,796		Kasid et al.		Apr. 6, 2001
	EN	10/056,210		Kasid et al.		Jan. 28, 2002
	EO	10/411,931		Kasid et al.	Dec. 4, 2003	Apr. 10, 2003
	EP	10/411,930		Kasid et al.	Jan. 8, 2004	Apr. 10, 2003
	EQ	10/443,273		Gokhale et al.	Dec. 11, 2003	May 22, 2003
	ER	10/627,571		Kasid et al.	Apr. 29, 2004	Jan. 28, 2002
	ES	10/679,561		Kasid et al.	Jun. 3, 2004	Oct. 6, 2003
\vdash	ET	10/679,865		Kasid et al.	Jun. 17, 2004	Oct. 6, 2003
	EU	10/680,313		Kasid et al.	Aug. 19, 2004	Oct. 6, 2003
	1 EV	10/679,580		Kasid et al.	Dec. 9, 2004	Oct. 6, 2003

*	_	F	Foreign Patent Document				Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No
de	EW	WO	87/00195	A1	Celltech Limited	Jan. 15, 1987		
	EX	WO	90/03430	A1	Cetus Corporation	Apr. 5, 1990		1
	EY	WO	90/07936	A1	Chiron Corporation	Jul. 26, 1990		
	ΕZ	wo	90/11092	A1	Vical, Inc.	Oct. 4, 1990		
	FA	wo	91/00357	A1	Cayla	Jan. 10, 1991		X ⁺
	FB	WO	91/02805	A2	Viagene, Inc.	Mar. 7, 1991		
	FC	wo	91/10741	A1	Cell Genesys, Inc.	Jul. 25, 1991		
	FD	wo	91/14445	A1	Research Development Foundation	Oct. 3, 1991		
	FE	wo	92/05266	A2	Viagene, Inc.	Apr. 2, 1992		
	FF	WO	92/10578	A1	Bioption AB	Jun. 25, 1992		<u> </u>
	FG	wo	92/11033	A1	Arch Development Corporation	Jul. 9, 1992		1
	FH	WO	93/03769	A1	The United States of America, Department of Health and Human Services	Mar. 4, 1993		
	FI	wo	93/04170	A1	The United States of America, Department of Health and Human Services	Mar. 4, 1993	_	
	FJ	wo	93/06248	A1	The United States of America, Department of Health and Human Services	Apr. 1, 1993		
	FK	wo	93/09239	A1	Research Corporation Technologies	May 13, 1993		
	FL	wo	93/10218	A1	The United States of America, Department of Health and Human Services	May 27, 1993		
	FM	wo	93/11230	A1	Dynal AS	Jun. 10, 1993		
	FN	wo	93/19191	A1	Centre National De LA Recherche Scientifique	Sep. 30, 1993		Χ ⁺
	FO	wo	93/25234	A1	The Regents of the University of California	Dec. 23, 1993		

	. /								
R	$\langle \hat{l} \rangle$	FP	WO	93/25698	A1	The United States of America, Department of Health and Human	Dec. 23, 1993		
$\mathcal{L}\mathcal{V}$				04/00000	1 4	Services	Feb. 3, 1994		\dashv
L	-4	FQ	WO	94/02602	A1	Cell Genesys, Inc.			
		FR	wo	94/03622	A1	Imperial College of ?Science, Technology & Medicine	Feb. 17, 1994		
		FS	· WO	94/12649	A2	Genzyme Corporation	Jun. 9, 1994		
		FΤ	WO	94/15645	A1	Texas Biotechnology Corporation	Jul. 21, 1994		
	-	, FU	wo	94/21792	A2	Viagene, Inc.	Sep. 29, 1994		
	. 1	, F∨	wo	94/23697	A1	Depotech Corporation	Oct. 27, 1994		•
		FW	wo	94/28938	A1	The Regents of the University of Michigan	Dec. 22, 1994		
	V	FΧ	WO	95/00655	A1	Mc Master University	Jan. 5, 1995		\neg
	7	FY	WO	95/07994	A2	Viagene, Inc.	Mar. 23, 1995		\neg
	7	FZ	WO	95/11984	A2	Canji, Inc.	May 4, 1995		\neg
<u> </u>	7	GA	WO	95/13796	A1	Depotech Corporation	May 26, 1995		
	\vdash	∕GB	wo	95/27044	. A1	Bioption AB	Oct. 12, 1995		
	1	GC	WO	95/27069	A1	Smithkline Beecham Biologicals	Oct. 12, 1995		\neg
	17	GD	wo	95/30763	A2	Viagene, Inc.	Nov. 16, 1995		\neg
	17	GE	WO	96/30498	A1	Xenotech Incorporated	Oct. 3, 1996		
 	17	GF	wo	96/33735	A1	Cell Genesys, Inc.	Oct. 31, 1996		
 	17	GG	wo	96/34096	A1	Cell Genesys, Inc.	Oct. 31, 1996		
 	十つ	GH	wo	98/24893	A2	Abgenix, Inc.	Jun. 11, 1998	1	
	1	GI	wo	00/00157	A2	Georgetown University Medical Center	Jan. 6, 2000		
	7	GJ	wo	02/059337	A1	Georgetown University School of Medicine	Aug. 1, 2002		
	7	GK	wo	02/081639	A2	Georgetown University	Oct. 17, 2002		
	7	GL	wo	02/081640	A2	Georgetown University	Oct. 17, 2002		
	7	GM	wo	02/081641	A2	Georgetown University	Oct. 17, 2002		
	7	GN	wo	02/081642	A2	Georgetown University	Oct. 17, 2002		
	ナ	∕ G0	EP	36,776	A2	Genentech, Inc.	Sep. 30, 1981		
	1	GP	EP	0 127 839	A2	The Texas A&M University System	Dec. 12, 1984		
	77	GQ	EP	0 155 476	A1	Idaho Research Foundation	Sep. 25, 1985		
	77	GR	EP	0 244 234	A2	Alko Ltd.	Nov. 4, 1987		
	7	GS	EP	0 345 242	A2	Smithkline Biologicals S.A.	Dec. 6, 1989	Х	, +
	7		EP	0 415 731	A2	The Wellcome Foundation Limited	Mar. 6, 1991		
	77	GU.	EP	0 524 968	B1	Depotech Corporation	Feb. 3, 1993		
	7	GV	EP	1074617	A2	Helix Research Institute	Feb. 7, 2001		
4	1	GW	GB	2 200 651	A	Ayad Mohamed Khalaf Al- Sumidale	Aug. 10, 1988		

		OTHER - NON PATENT LITERATURE DOCUMENTS						
	Examiner Doc.		monage manner of the dethics (in or a first and a first and a first a first and a first an		lation			
	Initials	No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No**			
	12/12/12	GX	ALTSCHUL et al., Nucleic Acids Research, 25(17), 3389-3402 (1997)					
	1	GY	ALVAREZ et al., The Journal of Biological Chemistry, 266(23), 15277-15285 (1991)					
100		GZ	BARBA et al., Journal of Neurosurgery, 79(5), 729-735 (1993)					
•		HA	BACCARINI et al., The Journal of Biological Chemistry, 266(17), 10941-10945 (1991)					
		нв	BAIN et al., Gene Therapy, 1(S68), (1994)					
		НĊ	BALLANCE et al., Biochemical and Biophysical Research Communications, 112(1),					
			284-289 (1983)					
		HD	BARNES et al., Analytical Biochemistry, 102(2), 255 (1980)					
	TPA	HE	Basic and Clinical Immunology, 217-262 (Sites and Terr eds., Appleton & Lange, Norwalk, CT 1991)					
		HF	BEACH et al., Nature, 300(5894), 706-709 (1981)					
		HG	BELYAVSKY et al., Nucleic Acids Research 17(8), 2919-2932 (1989)					
		НН	BERKNER, BioTechniques, 6(7), 616-629 (1988)					
		HI	BERNS et al., Annals of The New York Academy of Sciences, 772, 95-104 (1995)					
	1	HJ	BOSHART et al., Cell, 41(2), 521 (1985)					

Sill !	Инк	BOWIE et al., Science, 247(4948), 1306-1310 (1990)	
	/HL	BRANCH et al., Trends in Biochemical Sciences, 23(266), 45-50 (1998)	
1	1 нм	BRUDER et al., Genes & Development, 6(4), 545-556 (1992)	
1	HN	BRUHN et al., Proceedings of the National Academy of Sciences of the United States of	
#	1	America, 89, 2307-2311 (1992)	
,	HO	BURUHAM et al., American Journal of Hospital Pharmacy 51(2), 210-218 (1994)	
——	THP	CAILLAUD et al., European Journal of Neuroscience, 5(10), 1287-1291 (1993)	
 		CAPLEN et al., Proceedings of the National Academy of Sciences of the United States	
	1 на	of America, 98(17) 9742-47 (2001)	İ
 	/		
 - -	HR_	CARBONELL et al., Gene, 73(2), 409-418 (1988)	
\vdash	1 HS	CARROLL et al., The Journal of Biological Chemistry, 266(23) 14964-14969 (1991)	
<u> </u>	<u> 1 H T</u>	CARPRINO et al., The Journal of Organic Chemistry, 37, 3404-3409 (1972)	
-7	HU	CHANG et al., Nature, 275(5681), 617-624 (1978)	
	 H∨	CHIN, "On the preparation and utilization of isolated and purified oligonucleotides",	
	V	Katherine R. Everett Law Library of the University of North Carolina, March 2002	
TRA	1/HW	CHOTHIA et al., Journal of Molecular Biology, 196(4) 901-917 (1987)	
	HX	CHUNG et al., Proceedings of the National Academy of Sciences of the United States	
1	l	of America, 88(11), 4981- (1991)	
7	HY	CLELAND et al., Critical Reviews in Therapeutic Drug Carrier Systems, 10(4), 307-377	
	L	(1993)	
	AZ	CONNELLY, Human Gene Therapy, 6(2), 185-193 (1995)	
 	IA	COZENS et al., Journal of Molecular Biology, 206(2), 261-280 (1989)	
<u> </u>	IB	CREGG et al., Molecular and Cellular Biology, 5(12), 3376-3385 (1985)	
	//ic	CUNNINGHAM et al., Science, 244(108), 1081-1085 (1989)	
├ ─			
	1 ID	CURIEL et al., Human Gene Therapy, 3(2), 147-154 (1992)	
 	1 IE	DAS et al., Journal of Bacteriology, 158(3), 1165-1167 (1984)	
	1 1F	DAVIDOW et al., Current Genetics, 10(1), 39-48 (1985)	
	1/1G	DAVIS, The New Biologist, 2(5), 410-419 (1990)	
1	1 IH	DAVIS et al., Enzyme Engineering, 4, 169-73 (1978)	<u></u>
-	11_	DAYHOFF et al., Atlas of Protein Sequence and Structure, 5(Supplement 3), 345-352	
		(1978)	
FM	! IJ	DE BOHR et al., Proceedings of the National Academy of Sciences of the United States	
030		of America, 80(1), 21-25 (1983)	
1	1/IK	DE LOUVENCOURT et al., Journal of Bacteriology, 154(2), 737-742 (1983)	
	111	DENT et al., Science, 257(5075), 1404-1407 (1992)	
	TIM	DEVARY et al., Cell, 71, 1081-1091 (1992)	
	IN	DE VOS et al., Science, 255(5042), 306-312 (1992)	
. ———	110	DIJKEMA et al., <i>The EMBO Journal</i> , 4(3), 761 (1985)	
	VIP	DINCHUK et al., The Journal of Biological Chemistry, 275(50), 39543-39554 (2000)	
	*		
 	<u> 10 </u>	DOWNING et al., Cell, 85(4), 597-605 (1996)	
	IR	ELBASHIR et al., Nature, 411(6836), 494-98 (2001)	
	<u> 18</u>	FABIAN et al., Molecular and Cellular Biology, 13(11), 7170 (1993)	
	7 17	FEDEROFF et al., Proceedings of the National Academy of Sciences of the United	
	<u> </u>	States of America, 89(5), 1636-40 (1992)	
	110	FELGER et al., Human Gene Therapy, 7(15), 1791-1793 (1996)	
	IV	FIERMONTE et al, The Journal of Biological Chemistry, 276(11), 8225-8230 (2001)	
	1 IW	FINCO et al., The Journal of Biological Chemistry, 268(24), 17676-17679 (1993)	
	才以	FINK et al., Annual Review of Neuroscience, 19, 265-87 (1992)	
 	/ iŷ	FLOTTE et al., Proceedings of the National Academy of Sciences of the United States	
1 1	1. ' '	of America, 90(22), 10613-10617 (1993)	
	/ IZ	FRIDEN et al., Science, 259, 373-377 (1993)	 -
			
-¥	- JA -	FRIESEN et al., The Molecular Biology of Baculoviruses, 31-49 (1986)	
2			
You	JB	GAILLARDIN et al., Current Genetics, 10, 49-58 (1985)	├ ───
2	JB JC	GALFRE et al., Methods in Enzymology; Immunochemical Techniques, 73, 3-46 (1981)	
2	JB		
2	JB JC	GALFRE et al., Methods in Enzymology; Immunochemical Techniques, 73, 3-46 (1981)	
2	JB JC JD	GALFRE et al., Methods in Enzymology; Immunochemical Techniques, 73, 3-46 (1981) GARDNER et al., The Journal of Biological Chemistry, 268(24) 1789617901(1993) GILLE et al., Nature, 358(6385), 414-417 (1992)	
Som	JB JC JD JE JF	GALFRE et al., Methods in Enzymology; Immunochemical Techniques, 73, 3-46 (1981) GARDNER et al., The Journal of Biological Chemistry, 268(24) 1789617901(1993) GILLE et al., Nature, 358(6385), 414-417 (1992) GLEESON et al., The Journal of General Microbiology, 132(12), 3459-3465 (1986)	
Som	JB JC JD JE JF JG	GALFRE et al., Methods in Enzymology; Immunochemical Techniques, 73, 3-46 (1981) GARDNER et al., The Journal of Biological Chemistry, 268(24) 1789617901(1993) GILLE et al., Nature, 358(6385), 414-417 (1992) GLEESON et al., The Journal of General Microbiology, 132(12), 3459-3465 (1986) GOEDDEL et al., Nature, 281(5732), 544 (1979)	
Som	JB JC JD JE JF	GALFRE et al., Methods in Enzymology; Immunochemical Techniques, 73, 3-46 (1981) GARDNER et al., The Journal of Biological Chemistry, 268(24) 1789617901(1993) GILLE et al., Nature, 358(6385), 414-417 (1992) GLEESON et al., The Journal of General Microbiology, 132(12), 3459-3465 (1986)	

10	JK	GORMAN et al., Proceedings of the National Academy of Sciences of the United States	1
K Y		of America, 79(22), 6777-6781 (1982)	
1	JL	GORUPPI et al., FEBS Letters, 415(1), 59-63 (1997)	
	JM	GREEN et al., Science, 281(5381), 1309-1312 (1998)	
	JN	GUZMAN et al., Circulation Research, 73(6), 1202-1207 (1993)	
	10	GUZMAN et al., Circulation, 88(6), 2838-2848 (1993)	
—	JP	HAM et al., <i>Methods in Enzymology</i> , 58, 44-93 (1979)	
	1/10	HEIDECKER et al., Molecular and Cellular Biology, 10(6), 2503-2512 (1990)	
	₹JR	HEIDECKER et al., Advances in Cancer Research, 58, 53-73 (1992)	
	. 1 JS	HIGGINS et al., Computer Applications in the Biosciences, 8(2), 189-191 (1992)	
	1 J T	HINNEN et al., Proceedings of the National Academy of Sciences, 75(4), 1929-1933	
		(1978)	
· ·	10	HOULDWORTH et al., Proceedings of the National Academy of Sciences of the United	
1	<u> </u>	States of America, 85(1), 377-381 (1988)	
	7/1/	HOWE et al., Cell, 71(2), 335-342 (1992)	
	JW	ITO et al., Journal of Bacteriology, 153(1), 163-168 (1983)	
	JX	JAFFE et al., Nature Genetics, 1(5), 372-378 (1992)	
\vdash	JY	JOLLY, Cancer Gene Therapy, 1(1), 51-64 (1994)	
\vdash			
	ک لیر ک	JONES et al., Nature, 321(6069), 522-525 (1986)	
\sqcup	/ KA	KAPLITT, Nature Genetics, 8(2), 148-154 (1994)	
	KB	KASID et al., Science, 238(4818), 1039-1041 (1987)	
	1 KC	KASID et al., Advances in Cancer Research, 61, 195-233 (1993)	
	"KD	KASID et al., Nature, 382(6594), 813-816 (1996)	
	/ KE	KASS BISLER et al., Proceedings of the National Academy of Sciences of the United	
1 . /		States of America, 90(24), 11498-11502 (1993) (KASS-EISLE2 et al.)	
—	KF	KELLY et al., The EMBO Journal, 4(2), 475-479 (1985)	
	KG	KELSON et al., Biochimica Et Biophysica Acta, 1335(1-2), 99-110 (1997)	
		KETTLEBOROUGH et al., Protein Engineering., 4(7), 773-83 (1991)	
<u> </u>	1 KH		
ļ	KI	KIMURA, <i>Human Gene Therapy</i> , <i>5</i> (7), 845-852 (1994)	
<u>L</u>	1 7 KJ	KISSIL et al., The EMBO Journal, 18(2), 353-362 (1999)	
	/_ /_KK	KIZAKA-KONDOH et al., Molecular and Cellular Biology, 12(11), 5078-5086 (1992)	
	1 KL	KOIDE et al., Proceedings of the National Academy of Sciences of the United States of	
	!	America, 90(18), 8683 (1993)	
	1 KM	KOLAROV et al., The Journal of Biological Chemistry, 265(21), 12711-12716 (1990)	
	VKN	KOLCH et al., Nature, 349(6308), 426-428 (1991)	
 	/ ко	KOLLS et al., Proceedings of the National Academy of Sciences of the United States of	
1 /		America, 91(1), 9215-219 (1994)	
	4,KP	KORIOTH et al., Gene, 150(2), 395-399 (1994)	
\vdash		KRUG et al., Methods in Enzymology; Guide to Molecular Cloning Techniques, 152,	
	/ KQ	316-325 (1987)	
\vdash	KR	KUNZE et al., Journal of Basic Microbiology, 25(2), 141-144 (1985)	-
\vdash			
	KS	KURTZ et al., Molecular and Cellular Biology, 6(1), 142 (1986)	
	KT	KYRIAKIS et al., Nature, 358(6385), 417-421 (1992)	
	1 KU	LAWSON et al., The Journal of Biological Chemistry, 263(29), 14812-14818 (1988)	
	1,KV	LEBACQ-VERHEYDEN et al., Molecular and Cellualr Biology, 8(8), 3129 (1988)	
	1.KW	LEE et al., The Journal of Biological Chemistry, 266(16), 10351-10357 (1991)	
	LKX	LEVERO et al., Gene, 101(2), 195-202 (1991)	
\vdash	KY	LI et al., Human Gene Therapy, 4(4), 403-409 (1993)	
H		LI et al., Proceedings of the National Academy of Sciences, 90(20), 9247-9251 (1993)	
\vdash	1 KZ		
+	/ LA	LIANG et al., Science, 257(5072), 967-971 (1992)	
\perp	J LB	LIM et al., Gene, 255, 35-42 (2000)	
	LC	LUCIAKOVA et al., Biochemical Journal, 352(2), 519-523 (2000)	<u> </u>
LT	/LD	LUCKOW et al., Bio/Technology, 6(1), 47-55 (1988)	L
	LE	MACDONALD et al., Molecular and Cellular Biology, 13(11), 6615-6620 (1993)	
	LF	MAEDA et al., Nature, 315(6020), 592-594 (1985)	
-+	LG	MARSHALL et al., Cell, 80(2), 179-185 (1995)	
		MARTENS et al., Analytical Biochemistry, 273(1), 20-31 (1999)	
1	LH		
	1 LI	MARTIN et al., <i>DNA</i> , 7(2), 99-106 (1988)	
	TLJ	MARZO et al., The Journal of Experimental Medicine, 187(8), 1261-1271 (1998)	
	1 LK	MENDELSON et al., Virology, 166, 154-165 (1988)	
	J- 1 LL	MERRIFIELD et al., Journal of the American Chemical Society, 85, 2149-2154 (1963)	T
_			

	سينج	. /		
Z	J773	LM	MILLER et al., Genetic Engineering, 8, 277-279 (1986) (Setlow et al. ed.)	
Γ	1	LN	MILLER, Annual Review of Microbiology, 42, 177-199 (1988)	
_ T		LO	MILSTEIN et al., Natyre, 256(5517), 495-497 (1975)	
ᅪ		∠ LP	MIYAJIMA et al., Gene, 58(2&3), 273-281 (1987)	
((†		1 to	MONIA et al., Nature Medicine, 2(6), 668-675 (1996)	
W -		LR	MORRISON et al., The Journal of Biological Chemistry, 268(23), 17309-17316 (1993)	
⊢	\dashv	LS	MORRISON et al., Proceedings of the National Academy of Sciences of the United	
	Ι,	, [States of America, 81(21), 6851-6855 (1984)	
H	-+	1 IT	MORRISON et al., Advances in Immunology, 44, 65-92 (1988)	
u		· 1,10	NAKAMURA et al., The Journal of Biological Chemistry, 274(32), 22476-22483 (1999)	
7		1 LV	NECKELMANN et al., Proceedings of the National Academy of Sciences of the United	
	ŀ	1 - 7	States of America, 84(21), 7580-7584 (1987)	
1	_	LW	OHMICHI et al., The Journal of Biological Chemistry, 267(21), 14604-14610 (1992)	
⊢		1 LX	OSTADE et al., Nature, 361(6409), 266-269 (1993)	
⊢		LY	PADLAN et al., <i>Molecular Immunology</i> , 28(4/5), 489-498 (1991)	
H			PADLAN et al., <i>Molecular Immunology</i> , 23(4/3), 469-430 (1991) PADLAN et al., <i>Molecular Immunology</i> , 31(3), 169-217 (1994)	
b	-+	A LZ		
V.	\dashv	/MA	PATEL et al., Molecular Carcinogenesis, 18(1), 1-6 (1997)	
L	\dashv	1 M B	PATEL et al., ACTA Oncological, 37(5), 475-478 (1998) PFEIFER et al., Proceedings of the National Academy of Sciences of the United States	
d	- 1	MC	of America, 86(24),10075-10079 (1989)	
1	-+	MD	PFEIFER et al., Biochemical and Biophysical Research Communications, 252(1), 481-	
18	.	INI D	486 (1998)	1
싸	+	ME	PHILIP, Molecular and Cellular Biology, 14(4), 2411-2418 (1994)	
ŀ	-+	MF	PINCKARD et al., Clinical and Experimental Immunology, 2, 331-340 (1967)	·
ŀ		MG	PRASAD et al., Molecular and Cellular Biology, 12(11), 5260-5267 (1992)	
╌		MH	PULVERER et al., <i>Nature</i> , 353(6345), 670 (1991)	
M	+	MI	QURESHI et al., The Journal of Biological Chemistry, 266(31), 20594-20597 (1991)	
PY	+	W J	RAM et al., Cancer Research, 53(1), 83-88 (1993)	
- 1	-	MK	RAPP et al., The Oncogene Handbook, (Elsevier Science Publishers, New York), 213-	
ı		- INIK	253 (1988)	
ad	\dashv	* M L	RAPP, Oncogene, 6(4), 495-500 (1991)	
WH	_	MM	REBAY et al., Cell, 67, 687-699 (1991)	
All	-	MN	REES et al., The EMBO Journal, 7(7), 2053-2061 (1988)	
ም ት		MO	RIEDEL et al., European Journal of Immunology, 12, 3146-3150 (1993)	
ŀ	\dashv	/MP	ROBBINS et al., <i>Diabetes, 36(7),</i> 838-845 (1987)	
·		MQ	ROGERS et al., <i>Genomics</i> , 39(2), 127-135 (1997)	
ŀ	+	MR		
_ }	-	MS	ROSENFELD et al., Science, 252(5004), 431-434 (1991)	
- 1	-+	M T	SAMUELS et al., <i>Molecular and Cellular Biology</i> , 13(10), 6241-6252 (1993)	
ŀ			SAMULSKI et al., Journal of Virology, 63(9), 3822-3828 (1989)	
ł	-+	1 M U	SARUBBI et al., Analytical Biochemistry, 237(1), 70-75 (1996)	
}	-+	JMV M	OANODDI et al., Aliaiyuda biodheiliidiy, 207(1), 10-10 (1990)	
	1	- W	SCHAAP et al., The Journal of Biological Chemistry, 268(27), 20232-20236 (1993)	
ł	- 1	MX	SCHNEIDER et al., Tetrahedron Letters, 31(3), 335-338 (1990)	- 1.
ŀ	- 1	MY	SETH et al., The Journal of Biological Chemistry, 266(35), 23521 (1991)	
ŀ		MZ	SIEBENLIST et al., Cell, 20(1), 269 (1980)	
ŀ		NA NA	SIEGEL et al., The Journal of Immunology, 151(8), 4116-4127 (1993)	
ŀ		N B	SMITH et al., Proceedings of the National Academy of Sciences of the United States of	
]	- 1		America, 82(24), 8404-8408 (1985)	
ŀ		NC	SMITH et al., Journal of Molecular Biology, 224(4), 899-904 (1992)	
ŀ		ND	SMITH et al., Advances in Applied Mathematics, 2(4), 482-489 (1981)	
		NE	SOLDATENKOV et al., The Cancer Journal from Scientific American, 3(1), 13-20 (1997)	
41		NF	SOZERI et al., Oncogene, 7(11), 2259 (1992)	
내		NG	STANTON et al., Molecular and Cellular Biology, 9(2), 639-647 (1989)	
X		NH	STENFLO, Blood, 78(7). 1637-1651 (1991)	
41		NI	STOKOE et al., The EMBO Journal, 11(11), 3985-3994 (1992)	
		NJ	STURGILL et al., Nature, 334(6184), 715-718 (1988)	
A		NK	SUN et al., <i>Hepatology</i> , <i>27</i> (1), 228-239 (1998)	
Ч		NL NL	SUNNERHAGEN et al., The Journal of Biological Chemistry, 268(31), 2339-2344	 - -
D) NL	(1993)	
ANZ.		NM		
1		14 141	100. 0. 01., 01009010, 101.// 000./	

<u>. </u>	3 -	_ /				
Г	KL	34	NN	SUY et al., The Journal of Biological Chemistry, 273(28), 1787117878 (1998)		
Т	7		NO	TAKAMIYA et al., Journal of Neuroscience Research, 33(3), 493-503 (1992)		
\vdash	<u> </u>		NP	TILBURN et al., Gene, 26(2&3), 205-221 (1983)		
┢	{		NQ	TORNKVIST et al., The Journal of Biological Chemistry, 269(19), 13919-13921 (1994)		
┝			NR	TRAVERSE et al., Oncogene, 8(11), 3175-3181 (1993)		$\neg \neg$
\vdash				TURNER et al., Proceedings of the National Academy of Sciences of the United States		
ł		1	NS	of America, 90(12), 5544-5548 (1993)	1	
\vdash		 		UHLMANN et al., Chemical Reviews, 90(4), 543-584 (1990)		—-{
 -			MT			
L		-	NU	VAN DEN BERG et al., <i>Bio/Technology</i> , <i>8</i> (2), 135139 (1990)		
L	<u> </u>		ΝV	VERHOEYER et al., Science, 239(4847), 1534-1536 (1988)		
L			NW	VILE et al., Cancer Research., 53(5), 962-967 (1993)		
L			NX	VILE et al., Cancer Research, 53(17), 3860-3864 (1993)		
			NY_	VINCENT et al., Nature Genetics, 5, 130-134 (1993)		
			ΝZ	VLAK et al., The Journal of General Virology, 69(4) 765-776 (1988)		
Г			OA	WANG et al., Cell, 87(4), 629-638 (1996)		
			ОВ	WARNE et al., Nature, 364(6435), 352-355 (1993)]
一		+	ОС	WELLING et al., FEBS Letters, 188(2), 215-218 (1985)		
十		+	OD	WINITZ et al., The Journal of Biological Chemistry, 268(26), 19196-19199 (1993)		
 		1 1	OE	WOFFENDIN, Proceedings of the National Academy of Sciences of the United States of		
1			-	America, 91(24), 11581-11585 (1994)		
十		 	OF	WOTTEN et al., The Journal of Biological Chemistry, 268(24), 17975-17982 (1993)		
 		i	OG	WU, The Journal of Biological Chemistry, 264(29), 16985-16987 (1989)		
┢		╀┼	ОН	YELTON et al., Proceedings of the National Academy of Sciences of the United States		
		<u> </u>	011	of America, 81(5), 1470-1474 (1984)		
\mathbb{D}	700		01	ZABNER et al., Cell, 75(2), 207-216 (1993)		
۲⊢	300		Ol	ZHANG et al., <i>Nature</i> , 364(6435), 308-313 (1993)		
H	यम	n +				
⊢						
┝						
╌┠╌						
⊢						
-						
ᅡ						
L						
L					<u> </u>	
L						
Γ						
1						
F	-					
H	-					
卜						
┢		-+				
-					 	
-					 	
-					 	
ŀ					 	
L					 	
L	:				 	
]			 	
Γ					<u> </u>	
Ī						
Ì						
_						

Examiner Signature

Date Considered

A concise statement of relevance is being submitted in fleu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).